Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Stock Climbs 6.6 Percent After Positive Q3 Results

NEW YORK, Oct. 25 (GenomeWeb News) - Shares in Illumina were up 6.6 percent, or $.89, at $14.49 in mid-afternoon trading after the company announced positive third-quarter results yesterday.


As GenomeWeb News reported yesterday, Illumina had a 44-percent increase in third-quarter revenues and narrowed its quarterly net loss to $1.4 million from $2 million from a year ago. Illumina credited the increase in revenue to a "record" number of BeadStations shipped during the quarter.


Today, Illumina said it has sold a BeadStation system to PharmacoDesign that gives Illumina exclusive, licensed access to biomarkers discovered through disease studies.


Separately today, Illumina has asked the US Patent and Trademark Office to investigate the validity of a patent currently owned by Affymetrix that Illumina claims its scientists had originally invented.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.